Angiogenesis Antibodies

Angiogenesis antibodies neutralize growth factors and receptors that drive the formation of new blood vessels. Bevacizumab binds vascular endothelial growth factor A (VEGF-A) and blocks its interaction with VEGF receptors on endothelial cells. Faricimab is a bispecific antibody that binds both VEGF-A and angiopoietin-2 (ANG2), which destabilizes vessels through the TIE2 receptor. Further antibodies target VEGF receptor 2, delta-like ligand 4 (DLL4), platelet-derived growth factor (PDGF) receptors and endoglin. Typical uses include endothelial tube formation, vessel sprouting and retinal or tumor vascularization models.

Items 51-52 of 52

  • Vesencumab — antibody illustration
    Cat. No.
    AT1551

    Vesencumab

    Synonyms: MNRP-1685A

    Vesencumab (MNRP-1685A) is an IgG1 monoclonal antibody that targets neuropilin-1 (NRP-1), a co-receptor involved in angiogenesis and the enhancement of vascular endothelial growth factor (VEGF) signaling through its association with VEGFR-2. By binding to NRP-1, Vesencumab effectively inhibits the interaction between NRP-1 and VEGFR-2, thereby exerting anti-angiogenic and anti-neoplastic effects. This antibody is particularly useful in research focused on the mechanisms of metastasis and tumor growth in solid tumors, including studies on ovarian cancer.

    1 mg
    $384.00
    5 mg
    $1,000.00
    All 3 sizes
  • Valancitug
    Cat. No.
    B22008

    Valancitug

    Valancitug is a human monoclonal antibody specifically targeting Vascular Endothelial Growth Factor A (VEGFA). This antibody plays a crucial role in the regulation of angiogenesis and is essential for studies investigating vascular biology and associated diseases. It is widely utilized in research applications focused on cancer, ocular disorders, and other pathologies where VEGFA is implicated.

    Out of stock

    All 3 sizes

Items 51-52 of 52

Added to your cart

View Cart Checkout

    Loading...